Liaoning Cheng Da Co., Ltd. (SHA:600739)

China · Delayed Price · Currency is CNY

11.96

-0.02 (-0.17%)

May 8, 2026, 3:00 PM CST

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Biopharmaceutical	1.68B	-						1.28B	1.03B
Biopharmaceutical Growth	-	-						23.93%	9.14%
Energy Development	18.82M	-						90.41M	52.26M
Energy Development Growth	-	-						73.00%	-57.55%
Stock Headquarters	9.68M	-						64.58M	65.58M
Stock Headquarters Growth	-	-						-1.53%	69.18%
Domestic and Foreign Trade	9.58B	-						9.50B	4.58B
Domestic and Foreign Trade Growth	-	-						107.58%	-13.60%
Offset Of Business Segment	-3.62M	-						-57.46M	-58.85M
Pharmaceutical Chain	-	-						3.11B	3.07B
Pharmaceutical Chain Growth	-	-						1.30%	11.52%
Total	11.28B	-						13.99B	8.74B
Total Growth	-	-						60.06%	-4.26%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Mainland China	9.81B	-
Asia (Excl. Mainland China)	769.66M	-
Europe	31.54M	-
Americas	613.67M	-
Africa	59.76M	-
Oceania	783.69K	-
Total	11.29B	-

Source: S&P Global Market Intelligence.